Goyette Guillaume 2009 These.Pdf (8.250Mb)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Identification of Transcriptional Mechanisms Downstream of Nf1 Gene Defeciency in Malignant Peripheral Nerve Sheath Tumors Daochun Sun Wayne State University
Wayne State University DigitalCommons@WayneState Wayne State University Dissertations 1-1-2012 Identification of transcriptional mechanisms downstream of nf1 gene defeciency in malignant peripheral nerve sheath tumors Daochun Sun Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Recommended Citation Sun, Daochun, "Identification of transcriptional mechanisms downstream of nf1 gene defeciency in malignant peripheral nerve sheath tumors" (2012). Wayne State University Dissertations. Paper 558. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. IDENTIFICATION OF TRANSCRIPTIONAL MECHANISMS DOWNSTREAM OF NF1 GENE DEFECIENCY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS by DAOCHUN SUN DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2012 MAJOR: MOLECULAR BIOLOGY AND GENETICS Approved by: _______________________________________ Advisor Date _______________________________________ _______________________________________ _______________________________________ © COPYRIGHT BY DAOCHUN SUN 2012 All Rights Reserved DEDICATION This work is dedicated to my parents and my wife Ze Zheng for their continuous support and understanding during the years of my education. I could not achieve my goal without them. ii ACKNOWLEDGMENTS I would like to express tremendous appreciation to my mentor, Dr. Michael Tainsky. His guidance and encouragement throughout this project made this dissertation come true. I would also like to thank my committee members, Dr. Raymond Mattingly and Dr. John Reiners Jr. for their sustained attention to this project during the monthly NF1 group meetings and committee meetings, Dr. -
KLEIN-DISSERTATION-2014.Pdf (5.178Mb)
IDENTIFICATION AND CHARACTERIZATION OF THE MULTIFUNCTIONAL EPIGENETIC REGULATOR CFP1 AS AN ERK1/2 SUBSTRATE APPROVED BY SUPERVISORY COMMITTEE Melanie H. Cobb, Ph.D. Paul Sternweis, Ph.D. Joel Goodman, Ph.D. Nicholas Conrad, Ph.D. ii DEDICATION Thank you to all of the nerds, geeks and dorks who inspired and supported me through this endeavor, especially TJ, my parents, and Melanie. IDENTIFICATION AND CHARACTERIZATION OF THE MULTIFUNCTIONAL EPIGENETIC REGULATOR CFP1 AS AN ERK1/2 SUBSTRATE by AILEEN MELANIE KLEIN DISSERTATION Presented to the Faculty of the Graduate School of Biomedical Sciences The University of Texas Southwestern Medical Center at Dallas In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY The University of Texas Southwestern Medical Center at Dallas Dallas, Texas December, 2014 Copyright by Aileen Melanie Klein, 2014 All Rights Reserved IDENTIFICATION AND CHARACTERIZATION OF THE MULTIFUNCTIONAL EPIGENETIC REGULATOR CFP1 AS AN ERK1/2 SUBSTRATE Aileen Melanie Klein The University of Texas Southwestern Medical Center at Dallas, 2014 Supervising Professor: Melanie H. Cobb, Ph.D. Epigenetic regulation of gene transcription occurs as an integration of multiple layers of signals at a genetic locus. These signals can include local chromatin structure, covalent modifications to both histone proteins and DNA, the presence of transcription factors, and modification directly to the transcriptional machinery. Our lab is interested in the control of cellular processes by the mitogen activated protein kinases ERK1/2. In a yeast two-hybrid screen with activated ERK2 (extracellular signal-regulated kinase 2) to find novel interacting partners, our lab identified CFP1 (CxxC finger protein 1), a DNA-binding protein that is a vital component of the H3K4 trimethylating Set1A/B complexes to promote gene transcription. -
Transdifferentiation of Human Mesenchymal Stem Cells
Transdifferentiation of Human Mesenchymal Stem Cells Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Tatjana Schilling aus San Miguel de Tucuman, Argentinien Würzburg, 2007 Eingereicht am: Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Martin J. Müller Gutachter: PD Dr. Norbert Schütze Gutachter: Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am: Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig angefertigt und keine anderen als die von mir angegebenen Hilfsmittel und Quellen verwendet habe. Des Weiteren erkläre ich, dass diese Arbeit weder in gleicher noch in ähnlicher Form in einem Prüfungsverfahren vorgelegen hat und ich noch keinen Promotionsversuch unternommen habe. Gerbrunn, 4. Mai 2007 Tatjana Schilling Table of contents i Table of contents 1 Summary ........................................................................................................................ 1 1.1 Summary.................................................................................................................... 1 1.2 Zusammenfassung..................................................................................................... 2 2 Introduction.................................................................................................................... 4 2.1 Osteoporosis and the fatty degeneration of the bone marrow..................................... 4 2.2 Adipose and bone -
University of São Paulo
UNIVERSITY OF SÃO PAULO PHARMACEUTICAL SCIENCES FACULTY Department of Clinical and Toxicological Analysis Graduate Program in Pharmacy (Physiopathology and Toxicology) A non-targeted proteomics investigation of cylindrospermopsin-induced hepatotoxicity Carlos Andrey González Blanco Manuscript presented for the degree of P.h.D. Professor Advisor: Assoc. Prof. Ernani Pinto São Paulo 2017 UNIVERSIDADE DE SÃO PAULO FACULDADE DE CIÊNCIAS FARMACÊUTICAS Departamento de Analises Clinicas e Toxicológicas Programa de Pós-graduação em Farmacia (Fisiopatologia e Toxicologia) Uso de uma estratégia proteômica não-direcionada para investigar a hepatotoxicidade producida pela cilindrospermopsina Carlos Andrey González Blanco Versão corrigida da Tese conforme resolução CoPGr 6018 Tese para obtenção do Título de Doutor Orientador: Prof. Assoc. Ernani Pinto São Paulo 2017 CARLOS ANDREY GONZÁLEZ BLANCO A non-targeted proteomics investigation of cylindrospermopsin-induced hepatotoxicity Comissão Julgadora da Tese para obtenção do Título de Doutor Prof. Assoc. Ernani Pinto orientador/presidente _________________________________________________ 1o. examinador _________________________________________________ 2o. examinador __________________________________________________ 3o. examinador __________________________________________________ 4o. examinador São Paulo, ______ de _______________ de 2017 i “The map is not the territory”. A. Korzybski ii Acknowledgement I would like to thank my thesis advisor Prof. Ernani for his unconditional support and friendship. Throughout the years, I saw you taking risks in projects and making daring decisions in your academic career, which always turned up right. The audacity I saw in your work inspired me to strive harder and try out new ideas. I would also like to thank all the students I met throught the years at prof. Ernani`s lab, all of which are and will always be great friends; I learned something from each and every one of you. -
How Abnormal RNA Metabolism Results in Childhood-Onset Neurological Diseases
Exosomal Protein Deficiencies: How Abnormal RNA Metabolism Results in Childhood-Onset Neurological Diseases A thesis submitted for the degree of Doctor of Philosophy at Newcastle University October 2016 Michele Giunta Institute of Genetic Medicine ii Author’s declaration This thesis is submitted for the degree of Doctor of Philosophy at Newcastle University. I, Michele Giunta, declare that the work described here is my own, unless where clearly acknowledged and stated otherwise. I certify that I have not submitted any of the material in this thesis for a degree qualification at this or any other university. iii Abstract RNA metabolism is of critical importance for normal cellular functions and needs to be finely tuned in order to maintain stable conditions within the cell. The exosome complex is the most important RNA processing machinery, responsible for the correct processing of many different types of RNAs and interacting with different co-factors which bind and carry specific subtypes of RNA for degradation to the complex. Mutations in exosome complex subunits (EXOSC3, EXOSC8) were reported to cause severe childhood onset complex neurological disorders presenting with pontocerebellar hypoplasia type 1 (PCH1), spinal muscular atrophy (SMA) and central nervous system hypomyelination. We have recently identified a homozygous pathogenic mutation in RNA Binding Motif Protein 7 RBM7, a subunit of the nuclear exosome targeting (NEXT) complex in a single patient with SMA-like phenotype and proved that RBM7 is a novel human disease gene related to the exosome complex. In order to understand the disease mechanism in RBM7 deficiency and to explore the role of exosome complex in neurodevelopment, we performed gene expression studies (RT-PCR, RNA sequencing) in human cells of patients carrying mutations in EXOSC8 and RBM7. -
Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN. -
Mrna Expression in Human Leiomyoma and Eker Rats As Measured by Microarray Analysis
Table 3S: mRNA Expression in Human Leiomyoma and Eker Rats as Measured by Microarray Analysis Human_avg Rat_avg_ PENG_ Entrez. Human_ log2_ log2_ RAPAMYCIN Gene.Symbol Gene.ID Gene Description avg_tstat Human_FDR foldChange Rat_avg_tstat Rat_FDR foldChange _DN A1BG 1 alpha-1-B glycoprotein 4.982 9.52E-05 0.68 -0.8346 0.4639 -0.38 A1CF 29974 APOBEC1 complementation factor -0.08024 0.9541 -0.02 0.9141 0.421 0.10 A2BP1 54715 ataxin 2-binding protein 1 2.811 0.01093 0.65 0.07114 0.954 -0.01 A2LD1 87769 AIG2-like domain 1 -0.3033 0.8056 -0.09 -3.365 0.005704 -0.42 A2M 2 alpha-2-macroglobulin -0.8113 0.4691 -0.03 6.02 0 1.75 A4GALT 53947 alpha 1,4-galactosyltransferase 0.4383 0.7128 0.11 6.304 0 2.30 AACS 65985 acetoacetyl-CoA synthetase 0.3595 0.7664 0.03 3.534 0.00388 0.38 AADAC 13 arylacetamide deacetylase (esterase) 0.569 0.6216 0.16 0.005588 0.9968 0.00 AADAT 51166 aminoadipate aminotransferase -0.9577 0.3876 -0.11 0.8123 0.4752 0.24 AAK1 22848 AP2 associated kinase 1 -1.261 0.2505 -0.25 0.8232 0.4689 0.12 AAMP 14 angio-associated, migratory cell protein 0.873 0.4351 0.07 1.656 0.1476 0.06 AANAT 15 arylalkylamine N-acetyltransferase -0.3998 0.7394 -0.08 0.8486 0.456 0.18 AARS 16 alanyl-tRNA synthetase 5.517 0 0.34 8.616 0 0.69 AARS2 57505 alanyl-tRNA synthetase 2, mitochondrial (putative) 1.701 0.1158 0.35 0.5011 0.6622 0.07 AARSD1 80755 alanyl-tRNA synthetase domain containing 1 4.403 9.52E-05 0.52 1.279 0.2609 0.13 AASDH 132949 aminoadipate-semialdehyde dehydrogenase -0.8921 0.4247 -0.12 -2.564 0.02993 -0.32 AASDHPPT 60496 aminoadipate-semialdehyde -
Clinical Efficacy and Immune Regulation with Peanut Oral
Clinical efficacy and immune regulation with peanut oral immunotherapy Stacie M. Jones, MD,a Laurent Pons, PhD,b Joseph L. Roberts, MD, PhD,b Amy M. Scurlock, MD,a Tamara T. Perry, MD,a Mike Kulis, PhD,b Wayne G. Shreffler, MD, PhD,c Pamela Steele, CPNP,b Karen A. Henry, RN,a Margaret Adair, MD,b James M. Francis, PhD,d Stephen Durham, MD,d Brian P. Vickery, MD,b Xiaoping Zhong, MD, PhD,b and A. Wesley Burks, MDb Little Rock, Ark, Durham, NC, New York, NY, and London, United Kingdom Background: Oral immunotherapy (OIT) has been thought to noted during OIT resolved spontaneously or with induce clinical desensitization to allergenic foods, but trials antihistamines. By 6 months, titrated skin prick tests and coupling the clinical response and immunologic effects of peanut activation of basophils significantly declined. Peanut-specific OIT have not been reported. IgE decreased by 12 to 18 months, whereas IgG4 increased Objective: The study objective was to investigate the clinical significantly. Serum factors inhibited IgE–peanut complex efficacy and immunologic changes associated with OIT. formation in an IgE-facilitated allergen binding assay. Secretion Methods: Children with peanut allergy underwent an OIT of IL-10, IL-5, IFN-g, and TNF-a from PBMCs increased over protocol including initial day escalation, buildup, and a period of 6 to 12 months. Peanut-specific forkhead box protein maintenance phases, and then oral food challenge. Clinical 3 T cells increased until 12 months and decreased thereafter. In response and immunologic changes were evaluated. addition, T-cell microarrays showed downregulation of genes in Results: Of 29 subjects who completed the protocol, 27 ingested apoptotic pathways. -
Use of Microvesicles in Analyzing Nucleic Acid Profiles
(19) TZZ _T (11) EP 2 475 988 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12Q 1/6886 (2018.01) C12Q 1/6809 (2018.01) 14.11.2018 Bulletin 2018/46 C12Q 1/6806 (2018.01) (21) Application number: 10816090.4 (86) International application number: PCT/US2010/048293 (22) Date of filing: 09.09.2010 (87) International publication number: WO 2011/031877 (17.03.2011 Gazette 2011/11) (54) USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES VERWENDUNG VON MIKROVESIKELN BEI DER ANALYSE VON NUKLEINSÄUREPROFILEN UTILISATION DE MICROVÉSICULES DANS L’ANALYSE DE PROFILS D’ACIDE NUCLÉIQUE (84) Designated Contracting States: US-A1- 2005 003 426 US-A1- 2008 268 429 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • SKOG JOHAN ET AL: "Glioblastoma PL PT RO SE SI SK SM TR microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic (30) Priority: 09.09.2009 US 241014 P biomarkers", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, vol. 10, no. 12, 1 (43) Date of publication of application: December 2008 (2008-12-01), pages 1470-1476, 18.07.2012 Bulletin 2012/29 XP002526160, ISSN: 1465-7392, DOI: 10.1038/NCB1800 [retrieved on 2008-11-16] (60) Divisional application: • TAYLOR D D ET AL: "MicroRNA signatures of 18199345.2 tumor-derived exosomes as diagnostic biomarkers of ovarian cancer", GYNECOLOGIC (73) Proprietor: The General Hospital Corporation ONCOLOGY, ACADEMIC PRESS, LONDON, GB, Boston, MA 02114 (US) vol. -
Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses by a Synthetic TLR3 Ligand Mitigates
Downloaded from http://www.jimmunol.org/ by guest on September 28, 2021 Inducing is online at: average * The Journal of Immunology published online 16 August 2013 from submission to initial decision 4 weeks from acceptance to publication http://www.jimmunol.org/content/early/2013/08/16/jimmun ol.1300376 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 28, 2021. Published August 16, 2013, doi:10.4049/jimmunol.1300376 The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN. -
1 a Novel Prognostic Two-Gene Signature for Triple Negative Breast
A Novel Prognostic Two-Gene Signature for Triple Negative Breast Cancer Mansour A Alsaleem 1,2, Graham Ball 3, Michael S Toss 1, Sara Raafat 1, Mohammed Aleskandarany 1,4, Chitra Joseph 1, Angela Ogden 5, Shristi Bhattarai 5, Padmashree C G Rida 5, Francesca Khani 6, Melissa Davis 7, Olivier Elemento 8, Ritu Aneja 5, Ian O Ellis 1, Andrew Green 1, Nigel P Mongan 9,10 and Emad Rakha 1,4,11. 1 Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK. 2 Faculty of Applied Medical Sciences, Onizah Community College, Qassim University, Qassim, Saudi Arabia. 3 John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK 4 Faculty of Medicine, Menoufyia University, Shebin El Kom, Egypt. 5 Department of Biology, Georgia State University, Atlanta, GA, USA. 6 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA 7 Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA. 8 Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine of Cornell University, New York, NY, USA 9 University of Nottingham Biodiscovery Institute, Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK. 10 Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA. 11 Department of Histopathology, Division of Cancer and Stem Cells, School of Medicine, The University